Better identification and management of sleep apnoea and associated vascular risk factors in midlife may provide an important opportunity to support long-term brain health, according to new research from Monash University.

Researchers at the Technion – Israel Institute of Technology have developed a new class of dual-targeting PROTAC (protein degrader) molecules that selectively eliminate aggressive, treatment-resistant cancer cells while largely sparing healthy cells. Published in Oncogene, the study introduces compounds that simultaneously degrade two proteins critical for cancer cell survival: RNF4, which supports the stability of cancer-promoting proteins, and VHL, which suppresses ferroptosis, a form of programmed cell death. The approach proved effective against melanoma and sarcoma cells, including tumors resistant to existing therapies and patient-derived bone cancer cells. Cancer cells were eliminated within hours, while healthy cells were minimally affected. The findings demonstrate the potential of targeted protein degradation as a precision medicine strategy for overcoming therapeutic resistance in aggressive cancers. Further studies in animal models and clinical trials will be required to establish the safety and efficacy of this approach before it can be translated into clinical practice.

A new review article published in The Open Biochemistry Journal by Dr. Maria Trapali of the Laboratory of Chemistry, Biochemistry and Cosmetic Science, Department of Biomedical Medicine, University of West Attica, Egaleo, Attiki, Greece — together with co‑authors Sara Ouari, Nadia Benzidane, Lekhmici Arrar, and Noureddine Bribi

The scale of the problem is immense: in 2024, the International Diabetes Federation estimated that approximately 589 million adults worldwide were living with diabetes, with more than 80 percent of cases concentrated in low‑ and middle‑income countries where access to standard treatment is limited. Conventional drugs carry side effects, keeping interest in plant‑based alternatives strong. This review set out to move beyond traditional claims and evaluate what the scientific literature reveals — at the molecular level — about how these plants exert anti‑diabetic effects.

A new review article published in The Open Biochemistry Journal by Dr. Maria Trapali of the Laboratory of Chemistry, Biochemistry and Cosmetic Science, Department of Biomedical Medicine, University of West Attica, Egaleo, Attiki, Greece — together with co‑authors Sara Ouari, Nadia Benzidane, Lekhmici Arrar, and Noureddine Bribi

The scale of the problem is immense: in 2024, the International Diabetes Federation estimated that approximately 589 million adults worldwide were living with diabetes, with more than 80 percent of cases concentrated in low‑ and middle‑income countries where access to standard treatment is limited. Conventional drugs carry side effects, keeping interest in plant‑based alternatives strong. This review set out to move beyond traditional claims and evaluate what the scientific literature reveals — at the molecular level — about how these plants exert anti‑diabetic effects.

Nearly one in three early-career researchers (ECRs) report elevated psychological distress, according to the largest and most comprehensive meta-analysis to date on mental health among ECRs. Researchers from the University of Vienna synthesized evidence from almost 230 independent samples across nearly 150 studies, comprising close to 140,000 ECRs, to estimate the prevalence and severity of mental health problems in this population. The findings were published in Nature Human Behaviour.

Family- and individual-based therapy both help children with avoidant restrictive food intake disorder eat more foods, while family-based therapy also boosts weight gain.